newsfilter
← Latest News
GlobeNewswire·

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMouflage phase 1 trial